References
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020 Feb 24;323(13):1239. [Epub ahead of print].
- Lee PI, Hu YL, Chen PY, et al. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020 Feb 25. [Epub ahead of print]. DOI:10.1016/j.jmii.2020.02.011.
- Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020 Feb 4;53:pii: S1684-1182(20)30011–6. [Epub ahead of print].
- Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar 13;34:101623. [Epub ahead of print].
- Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020;13(5):667–673. .
- Zumla A, Chan JF, Azhar EI, et al. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–347.
- Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–150.
- Medrxiv News. [cited 2020 April 12]. Available from: https://times.hinet.net/mobile/news/22831665;
- Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020 Apr 10. [Epub ahead of print]. DOI:10.1056/NEJMoa2007016
- Wang Y, Fan G, Salam A, et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J Infect Dis. 2019;221(10):1688–1698. .
- Novel coronavirus pneumonia diagnosis and treatment plan (provisional 7th edition, in Chinese). [cited 2020 Apr 12]. Available from: https://www.chinalawtranslate.com/coronavirus-treatment-plan-7/
- Chan JFW, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904–1913. .
- Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256. .
- Cao B, Wang Y, Wen D, et al., A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382(19):1787–1799. .
- Cush J NIH Consensus Guidelines for the Treatment of COVID-19, 2020 April 22. [cited 2020 May 1]. Available from: http://rheumnow.com/content/nih-consensus-guidelines-treatment-covid-19
- Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
- Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19 Use of these drugs is premature and potentially harmful. BMJ. 2020;369:m1432.
- Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9:pii: ciaa237. [Epub ahead of print]. DOI:10.1093/cid/ciaa237.
- NEJM Journal Watch. COVID-19 update: hydroxychloroquine & recovery time/home face masks at work/reusing respirators. 2020 April 1 [cited 2020 Apr 5]. Available form: https://www.jwatch.org/fw116513/2020/04/01/covid-19-update-hydroxychloroquine-recovery-time-home
- Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial (preprint). MedRxIV; 2020 Mar 31 [cited 2020 Apr 11] Available from: https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2.full.pdf
- Gautret P, Lagier J, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949. [Epub ahead of print]. DOI:10.1016/j.ijantimicag.2020.105949.
- News. FDA approves COVACTA trial for RA drug Actemra in COVID-19 patients. [cited 2020 Mar 28]. Available from: https://www.pharmaceutical-business-review.com/news/covacta-trial-actemra-covid-19/
- Medscape. Treatment of coronavirus disease 2019 (COVID-19): investigational drugs and other therapies: introduction, investigational antiviral agents, immunomodulators and other investigational therapies. [cited 2020 Apr 10]. Available from: https://emedicine.medscape.com/article/2500116-overview
- News. Incyte announces plans to initiate a phase 3 clinical trial of ruxolitinib (Jakafi®) as a treatment for patients with COVID-19 associated cytokine storm. [cited 2020 Apr 11]. Available from: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-plans-initiate-phase-3-clinical-trial
- Wang Y, Cui R, Li G, et al. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antiviral Res. 2016;125:1–7.
- Zhou N, Pan T, Zhang J, et al., Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV). J Biol Chem. 2016;291(17):9218–9232.
- Baron SA, Devaux C, Colson P, et al. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Int J Antimicrob Agents. 2020;55(4):105944. .
- González Canga Q, Sahagún Prieto AM, José Diez Liébana M, et al. The pharmacokinetics and interactions of ivermectin in humans–a mini-review. Aaps J. 2008;10(1):42–46. .
- Sajid MS, Iqbal Z, Muhammad G, et al. Immunomodulatory effect of various anti-parasitics: a review. Parasitology. 2006;132(3):301–313.
- Wagstaff KM, Rawlinson SM, Hearps AC, et al. An AlphaScreen®-based assay for high-throughput screening for specific inhibitors of nuclear import. J Biomol Screen. 2011;16(2):192–200. .
- Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Mar 29 [cited 2020 Apr 8];178:104787. Available from: file:///C:/Users/doctorw7/Downloads/The%20FDA-approved%20Drug% 20Ivermectin%20inhibits%20the%20replication%20of%20SARS-CoV-2%20in%20vitro.pdf
- Caly L, Wagstaff KM, Jans DA. Nuclear trafficking of proteins from RNA viruses: potential target for antivirals? Antiviral Res. 2012;95(3):202–206.
- Chandler RE. Serious neurological adverse events after ivermectin-Do they occur beyond the Indication of onchocerciasis? Am J Trop Med Hyg. 2018;98(2):382–388.
- Navarro M, Camprubí D, Requena-Méndez A, et al., Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020;75(4):827–834. .
- A randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in treating inflammatory lung injury and improving clinical outcomes associated with severe or critical COVID-19. (ClinicalTrials.gov NCT04326426). [cited 2020 April 10]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04326426?term=tradipitant&cond=COVID&draw=2&rank=1
- Chen L, Liu P, Gao H, et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis. 2004;39(10):1531–1535. .
- Society of critical care medicine. COVID-19 Guidelines. [cited 2020 May 1]. Available from: https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19
- Fedson DS. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med. 2016;4(21):421.
- Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. mBio. 2020;11:e00398–20.
- Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020 Apr 4;53:pii: S1684-1182(20)30094–3. [Epub ahead of print].